Reviewing Caladrius Biosciences (CLBS) & Tivity Health (TVTY)

Caladrius Biosciences (NASDAQ: CLBS) and Tivity Health (NASDAQ:TVTY) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends.

Earnings and Valuation

This table compares Caladrius Biosciences and Tivity Health’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Caladrius Biosciences $35.28 million 1.25 $22.97 million ($1.78) -2.60
Tivity Health $556.94 million 2.87 $63.71 million $1.68 23.84

Tivity Health has higher revenue and earnings than Caladrius Biosciences. Caladrius Biosciences is trading at a lower price-to-earnings ratio than Tivity Health, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

5.7% of Caladrius Biosciences shares are held by institutional investors. 13.1% of Caladrius Biosciences shares are held by insiders. Comparatively, 8.4% of Tivity Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Caladrius Biosciences has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Tivity Health has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Caladrius Biosciences and Tivity Health, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caladrius Biosciences 0 0 2 0 3.00
Tivity Health 0 1 6 0 2.86

Caladrius Biosciences presently has a consensus price target of $9.50, indicating a potential upside of 105.18%. Tivity Health has a consensus price target of $47.14, indicating a potential upside of 17.71%. Given Caladrius Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Caladrius Biosciences is more favorable than Tivity Health.

Profitability

This table compares Caladrius Biosciences and Tivity Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Caladrius Biosciences N/A -62.53% -38.56%
Tivity Health 11.44% 29.17% 11.27%

Summary

Tivity Health beats Caladrius Biosciences on 9 of the 14 factors compared between the two stocks.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.

About Tivity Health

Tivity Health, Inc. provides fitness and health improvement programs in the United States. The company offers SilverSneakers senior fitness program to the members of Medicare advantage, Medicare supplement, and group retiree plans; and Prime fitness, a fitness facility access program through commercial health plans and employers. It also provides health plans through WholeHealth Living program; and health services, such as chiropractic care, acupuncture, physical therapy, occupational therapy, speech therapy, and others. The company was formerly known as Healthways, Inc. and changed its name to Tivity Health, Inc. in January 2017. Tivity Health, Inc. was founded in 1981 and is headquartered in Franklin, Tennessee.

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Research Analysts’ Updated EPS Estimates for May, 23rd
Research Analysts’ Updated EPS Estimates for May, 23rd
Chart Industries Sees Unusually High Options Volume
Chart Industries Sees Unusually High Options Volume
Littelfuse, Inc.  Receives $217.00 Consensus Price Target from Analysts
Littelfuse, Inc. Receives $217.00 Consensus Price Target from Analysts
Orix  Stake Increased by M&T Bank Corp
Orix Stake Increased by M&T Bank Corp
12,910 Shares in Synaptics, Incorporated  Purchased by M&T Bank Corp
12,910 Shares in Synaptics, Incorporated Purchased by M&T Bank Corp
M&T Bank Corp Has $617,000 Holdings in WellCare
M&T Bank Corp Has $617,000 Holdings in WellCare


© 2006-2018 Ticker Report. Google+.